Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have earned an average rating of “Moderate Buy” from the ten research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $51.75.
Several analysts have recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a report on Tuesday, August 6th. Chardan Capital reaffirmed a “buy” rating and issued a $62.00 target price on shares of Rocket Pharmaceuticals in a report on Tuesday, August 6th. Canaccord Genuity Group decreased their price target on Rocket Pharmaceuticals from $49.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, July 3rd. Needham & Company LLC reissued a “buy” rating and issued a $52.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. Finally, William Blair restated an “outperform” rating on shares of Rocket Pharmaceuticals in a research note on Monday, June 3rd.
Get Our Latest Analysis on Rocket Pharmaceuticals
Rocket Pharmaceuticals Trading Up 0.5 %
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.02). During the same period in the previous year, the firm earned ($0.82) earnings per share. As a group, research analysts predict that Rocket Pharmaceuticals will post -2.96 earnings per share for the current fiscal year.
Insider Buying and Selling at Rocket Pharmaceuticals
In other news, insider Mark Andrew White sold 3,026 shares of the stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $20.39, for a total transaction of $61,700.14. Following the sale, the insider now owns 72,220 shares in the company, valued at $1,472,565.80. The transaction was disclosed in a filing with the SEC, which is available at this link. 31.10% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of RCKT. Nisa Investment Advisors LLC increased its stake in shares of Rocket Pharmaceuticals by 31.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 764 shares in the last quarter. Old Well Partners LLC purchased a new stake in Rocket Pharmaceuticals in the 4th quarter worth $200,000. Capstone Investment Advisors LLC bought a new stake in Rocket Pharmaceuticals during the fourth quarter valued at about $217,000. Amalgamated Bank lifted its position in shares of Rocket Pharmaceuticals by 5.4% in the fourth quarter. Amalgamated Bank now owns 8,653 shares of the biotechnology company’s stock valued at $259,000 after acquiring an additional 440 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Rocket Pharmaceuticals in the fourth quarter worth about $332,000. Institutional investors own 98.39% of the company’s stock.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Read More
- Five stocks we like better than Rocket Pharmaceuticals
- What Are Dividend Champions? How to Invest in the Champions
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- Why Invest in High-Yield Dividend Stocks?
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 8/19 – 8/23
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.